Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline.

Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in non-infectious uveitis, which adds up to other four new Phase II trials that were launched earlier this year in Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, and lupus erythematosus.

Though these diseases are very different to each other, the trials are based in filgotinib’s ability to block JAK1, a protein involved in multiple inflammatory signaling pathways. This new indication will make the team step into ophthalmic diseases, where a number of biotechs are already developing their own approaches to treat uveitis. Among them are Elasmogen, developing small, shark-inspired antibodiesTxCell, working on a cell therapy; and Eyevensys, which is going after a virus-free gene therapy.

Image via D. Kucharski K. Kucharska / Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.